{"id":"NCT03306264","sponsor":"Astex Pharmaceuticals, Inc.","briefTitle":"Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML","officialTitle":"A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-15","primaryCompletion":"2021-09-10","completion":"2023-05-25","firstPosted":"2017-10-11","resultsPosted":"2024-07-01","lastUpdate":"2024-08-27"},"enrollment":227,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myelodysplastic Syndromes","Chronic Myelomonocytic Leukemia","Acute Myeloid Leukemia"],"interventions":[{"type":"DRUG","name":"ASTX727","otherNames":["decitabine 35 mg + cedazuridine 100 mg"]},{"type":"DRUG","name":"Dacogen","otherNames":["decitabine"]}],"arms":[{"label":"MDS or CMML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727","type":"EXPERIMENTAL"},{"label":"MDS or CMML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727","type":"EXPERIMENTAL"},{"label":"AML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727","type":"EXPERIMENTAL"},{"label":"AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727","type":"EXPERIMENTAL"}],"summary":"Multicenter PK study of ASTX727 versus IV decitabine. Adult participants who were candidates to receive IV decitabine were randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine 20 mg/m\\^2 Daily×5 in Cycle 2, or the converse order. After completion of PK studies during the first 2 treatment cycles, participants continued to receive treatment with ASTX727 from Cycle 3 onward (in 28-day cycles) until disease progression, unacceptable toxicity, or the participants discontinued treatment or withdrew from the study.","primaryOutcome":{"measure":"Total 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV Decitabine","timeFrame":"ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)","effectByArm":[{"arm":"MDS or CMML: IV Decitabine","deltaMin":864.34,"sd":40},{"arm":"MDS or CMML: ASTX727","deltaMin":855.96,"sd":50.6},{"arm":"AML: IV Decitabine","deltaMin":910.1,"sd":52.4},{"arm":"AML: ASTX727","deltaMin":900.5,"sd":52}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG002 vs OG003","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":84,"countries":["United States","Austria","Canada","Czechia","France","Germany","Hungary","Italy","Spain","United Kingdom"]},"refs":{"pmids":["38135371"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":132},"commonTop":["Thrombocytopenia","Anaemia","Neutropenia","Constipation","Nausea"]}}